Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

2.

Researchers can now forecast how prostate cancer bone metastases will react to radium-223 treatment.

3.

The Kansas Cancer Center awarded two Indian American doctors professorships.

4.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

5.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot